Pricing Log in Create free account

Alzamend Neuro, Inc. (ALZN) vs Aprea Therapeutics, Inc. (APRE)

Alzamend Neuro, Inc. and Aprea Therapeutics, Inc. are both Biotechnology companies. Alzamend Neuro, Inc. and Aprea Therapeutics, Inc. are of similar size ($6.3M and $6.3M). Across the 10 metrics below, Aprea Therapeutics, Inc. leads on 7 and Alzamend Neuro, Inc. on 3.

Valuation

Metric ALZN APRE Biotechnology median
P/E n/m n/m 11.19
P/S n/m 82.67 9.15
P/B 1.01 0.69 2.23
Price to free cash flow n/m n/m 26.14
EV/EBITDA 0.16 0.93 0.71
EV/Sales n/m (49.80) 8.65
Earnings yield (175.57%) (159.00%) (33.82%)
Free cash flow yield (121.76%) (53.94%) (23.58%)

Profitability

Metric ALZN APRE Biotechnology median
Gross margin 0.00% 100.00% 68.27%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (163.23%) (62.83%) (50.82%)
Return on assets (122.36%) (53.24%) (46.08%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALZN APRE Biotechnology median
Revenue growth (TTM) — (80.99%) 7.42%
EPS growth (last fiscal year) 76.77% 17.87% 29.86%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALZN APRE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.01 9.67 4.72
Net debt to EBITDA 0.08 1.11 1.01

Dividend

Metric ALZN APRE Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ALZN APRE Biotechnology median
Market cap 6.27m 6.25m 176.65m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack